Collectively, our data demonstrate the efficacy of the BAY 41-2272 compound in counteracting human conjunctival fibroblast-to-myofibroblast transition, thus paving the way for the potential employment of sGC stimulators as new adjuvant therapeutic agents for the treatment of conjunctival fibrotic conditions such as in pterygium or glaucoma. Here, SGCB is linked to glaucoma.